Ventyx Biosciences, Inc. (VTYX) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress
August 7, 2025 4:05 PM EDTPositive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinsons disease Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025 Phase 2 study of VTX3232 in participants with obesity and cardiometabolic risk factors is fully-enrolled and on track to yield topline data in early Q4 2025 Cash, cash equivalents and marketable securities balance of $209.0M as of
June 30, 2025 expected to fund planned operations into at least H2 2026
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ventyx... More
